Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb

Author's Avatar
Apr 08, 2022
  • THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB
  • EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICALS